Zobrazeno 1 - 10
of 1 351
pro vyhledávání: '"Daviskas E"'
Autor:
Anderson S; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (S.A.); Inhaled Delivery Solutions LLC, Durham, North Carolina (P.A.); Emmace Consulting AB Medicon Village, Lund, Sweden (P.B., H.L., B.O.); Insmed Inc., Bridgewater, New Jersey (D.C.); Aerogen Pharma Corporation, San Mateo, California (A.C.); Woolcock Institute of Medical Research, Glebe, New South Wales, Australia (E.D.); Drug Development, Pharmacology and Clinical Pharmacology Consulting, Mainz, Germany (B.D.); Preferred Regulatory Consulting, San Mateo, California (P.E-.D.); Clayton, CA (R.F.); Respidex LLC, Dennis, Massachusetts (I.G.); and cystetic Medicines, Inc., Burlingame, California (J.W.)., Atkins P; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (S.A.); Inhaled Delivery Solutions LLC, Durham, North Carolina (P.A.); Emmace Consulting AB Medicon Village, Lund, Sweden (P.B., H.L., B.O.); Insmed Inc., Bridgewater, New Jersey (D.C.); Aerogen Pharma Corporation, San Mateo, California (A.C.); Woolcock Institute of Medical Research, Glebe, New South Wales, Australia (E.D.); Drug Development, Pharmacology and Clinical Pharmacology Consulting, Mainz, Germany (B.D.); Preferred Regulatory Consulting, San Mateo, California (P.E-.D.); Clayton, CA (R.F.); Respidex LLC, Dennis, Massachusetts (I.G.); and cystetic Medicines, Inc., Burlingame, California (J.W.)., Bäckman P; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (S.A.); Inhaled Delivery Solutions LLC, Durham, North Carolina (P.A.); Emmace Consulting AB Medicon Village, Lund, Sweden (P.B., H.L., B.O.); Insmed Inc., Bridgewater, New Jersey (D.C.); Aerogen Pharma Corporation, San Mateo, California (A.C.); Woolcock Institute of Medical Research, Glebe, New South Wales, Australia (E.D.); Drug Development, Pharmacology and Clinical Pharmacology Consulting, Mainz, Germany (B.D.); Preferred Regulatory Consulting, San Mateo, California (P.E-.D.); Clayton, CA (R.F.); Respidex LLC, Dennis, Massachusetts (I.G.); and cystetic Medicines, Inc., Burlingame, California (J.W.)., Cipolla D; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (S.A.); Inhaled Delivery Solutions LLC, Durham, North Carolina (P.A.); Emmace Consulting AB Medicon Village, Lund, Sweden (P.B., H.L., B.O.); Insmed Inc., Bridgewater, New Jersey (D.C.); Aerogen Pharma Corporation, San Mateo, California (A.C.); Woolcock Institute of Medical Research, Glebe, New South Wales, Australia (E.D.); Drug Development, Pharmacology and Clinical Pharmacology Consulting, Mainz, Germany (B.D.); Preferred Regulatory Consulting, San Mateo, California (P.E-.D.); Clayton, CA (R.F.); Respidex LLC, Dennis, Massachusetts (I.G.); and cystetic Medicines, Inc., Burlingame, California (J.W.)., Clark A; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (S.A.); Inhaled Delivery Solutions LLC, Durham, North Carolina (P.A.); Emmace Consulting AB Medicon Village, Lund, Sweden (P.B., H.L., B.O.); Insmed Inc., Bridgewater, New Jersey (D.C.); Aerogen Pharma Corporation, San Mateo, California (A.C.); Woolcock Institute of Medical Research, Glebe, New South Wales, Australia (E.D.); Drug Development, Pharmacology and Clinical Pharmacology Consulting, Mainz, Germany (B.D.); Preferred Regulatory Consulting, San Mateo, California (P.E-.D.); Clayton, CA (R.F.); Respidex LLC, Dennis, Massachusetts (I.G.); and cystetic Medicines, Inc., Burlingame, California (J.W.)., Daviskas E; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (S.A.); Inhaled Delivery Solutions LLC, Durham, North Carolina (P.A.); Emmace Consulting AB Medicon Village, Lund, Sweden (P.B., H.L., B.O.); Insmed Inc., Bridgewater, New Jersey (D.C.); Aerogen Pharma Corporation, San Mateo, California (A.C.); Woolcock Institute of Medical Research, Glebe, New South Wales, Australia (E.D.); Drug Development, Pharmacology and Clinical Pharmacology Consulting, Mainz, Germany (B.D.); Preferred Regulatory Consulting, San Mateo, California (P.E-.D.); Clayton, CA (R.F.); Respidex LLC, Dennis, Massachusetts (I.G.); and cystetic Medicines, Inc., Burlingame, California (J.W.)., Disse B; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (S.A.); Inhaled Delivery Solutions LLC, Durham, North Carolina (P.A.); Emmace Consulting AB Medicon Village, Lund, Sweden (P.B., H.L., B.O.); Insmed Inc., Bridgewater, New Jersey (D.C.); Aerogen Pharma Corporation, San Mateo, California (A.C.); Woolcock Institute of Medical Research, Glebe, New South Wales, Australia (E.D.); Drug Development, Pharmacology and Clinical Pharmacology Consulting, Mainz, Germany (B.D.); Preferred Regulatory Consulting, San Mateo, California (P.E-.D.); Clayton, CA (R.F.); Respidex LLC, Dennis, Massachusetts (I.G.); and cystetic Medicines, Inc., Burlingame, California (J.W.)., Entcheva-Dimitrov P; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (S.A.); Inhaled Delivery Solutions LLC, Durham, North Carolina (P.A.); Emmace Consulting AB Medicon Village, Lund, Sweden (P.B., H.L., B.O.); Insmed Inc., Bridgewater, New Jersey (D.C.); Aerogen Pharma Corporation, San Mateo, California (A.C.); Woolcock Institute of Medical Research, Glebe, New South Wales, Australia (E.D.); Drug Development, Pharmacology and Clinical Pharmacology Consulting, Mainz, Germany (B.D.); Preferred Regulatory Consulting, San Mateo, California (P.E-.D.); Clayton, CA (R.F.); Respidex LLC, Dennis, Massachusetts (I.G.); and cystetic Medicines, Inc., Burlingame, California (J.W.)., Fuller R; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (S.A.); Inhaled Delivery Solutions LLC, Durham, North Carolina (P.A.); Emmace Consulting AB Medicon Village, Lund, Sweden (P.B., H.L., B.O.); Insmed Inc., Bridgewater, New Jersey (D.C.); Aerogen Pharma Corporation, San Mateo, California (A.C.); Woolcock Institute of Medical Research, Glebe, New South Wales, Australia (E.D.); Drug Development, Pharmacology and Clinical Pharmacology Consulting, Mainz, Germany (B.D.); Preferred Regulatory Consulting, San Mateo, California (P.E-.D.); Clayton, CA (R.F.); Respidex LLC, Dennis, Massachusetts (I.G.); and cystetic Medicines, Inc., Burlingame, California (J.W.)., Gonda I; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (S.A.); Inhaled Delivery Solutions LLC, Durham, North Carolina (P.A.); Emmace Consulting AB Medicon Village, Lund, Sweden (P.B., H.L., B.O.); Insmed Inc., Bridgewater, New Jersey (D.C.); Aerogen Pharma Corporation, San Mateo, California (A.C.); Woolcock Institute of Medical Research, Glebe, New South Wales, Australia (E.D.); Drug Development, Pharmacology and Clinical Pharmacology Consulting, Mainz, Germany (B.D.); Preferred Regulatory Consulting, San Mateo, California (P.E-.D.); Clayton, CA (R.F.); Respidex LLC, Dennis, Massachusetts (I.G.); and cystetic Medicines, Inc., Burlingame, California (J.W.) igonda@respidex.com., Lundbäck H; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (S.A.); Inhaled Delivery Solutions LLC, Durham, North Carolina (P.A.); Emmace Consulting AB Medicon Village, Lund, Sweden (P.B., H.L., B.O.); Insmed Inc., Bridgewater, New Jersey (D.C.); Aerogen Pharma Corporation, San Mateo, California (A.C.); Woolcock Institute of Medical Research, Glebe, New South Wales, Australia (E.D.); Drug Development, Pharmacology and Clinical Pharmacology Consulting, Mainz, Germany (B.D.); Preferred Regulatory Consulting, San Mateo, California (P.E-.D.); Clayton, CA (R.F.); Respidex LLC, Dennis, Massachusetts (I.G.); and cystetic Medicines, Inc., Burlingame, California (J.W.)., Olsson B; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (S.A.); Inhaled Delivery Solutions LLC, Durham, North Carolina (P.A.); Emmace Consulting AB Medicon Village, Lund, Sweden (P.B., H.L., B.O.); Insmed Inc., Bridgewater, New Jersey (D.C.); Aerogen Pharma Corporation, San Mateo, California (A.C.); Woolcock Institute of Medical Research, Glebe, New South Wales, Australia (E.D.); Drug Development, Pharmacology and Clinical Pharmacology Consulting, Mainz, Germany (B.D.); Preferred Regulatory Consulting, San Mateo, California (P.E-.D.); Clayton, CA (R.F.); Respidex LLC, Dennis, Massachusetts (I.G.); and cystetic Medicines, Inc., Burlingame, California (J.W.)., Weers J; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (S.A.); Inhaled Delivery Solutions LLC, Durham, North Carolina (P.A.); Emmace Consulting AB Medicon Village, Lund, Sweden (P.B., H.L., B.O.); Insmed Inc., Bridgewater, New Jersey (D.C.); Aerogen Pharma Corporation, San Mateo, California (A.C.); Woolcock Institute of Medical Research, Glebe, New South Wales, Australia (E.D.); Drug Development, Pharmacology and Clinical Pharmacology Consulting, Mainz, Germany (B.D.); Preferred Regulatory Consulting, San Mateo, California (P.E-.D.); Clayton, CA (R.F.); Respidex LLC, Dennis, Massachusetts (I.G.); and cystetic Medicines, Inc., Burlingame, California (J.W.).
Publikováno v:
Pharmacological reviews [Pharmacol Rev] 2022 Jan; Vol. 74 (1), pp. 48-118.
Autor:
Casula, Luca1 (AUTHOR) luca.casula@unica.it, Craparo, Emanuela Fabiola2 (AUTHOR) emanuela.craparo@unipa.it, Lai, Eleonora1 (AUTHOR) eleonora.lai4@unica.it, Scialabba, Cinzia2 (AUTHOR) cinzia.scialabba@unipa.it, Valenti, Donatella1 (AUTHOR) donatella.valenti@unica.it, Schlich, Michele1 (AUTHOR) michele.schlich@unica.it, Sinico, Chiara1 (AUTHOR) sinico@unica.it, Cavallaro, Gennara2 (AUTHOR) gennara.cavallaro@unipa.it, Lai, Francesco1 (AUTHOR) frlai@unica.it
Publikováno v:
Pharmaceuticals (14248247). Dec2024, Vol. 17 Issue 12, p1708. 16p.
Autor:
Alqasmi, Mohammed1 (AUTHOR) malqasmi@su.edu.sa
Publikováno v:
Journal of Clinical Medicine. Nov2024, Vol. 13 Issue 21, p6530. 21p.
Autor:
Bruneau, Cyrille1 (AUTHOR) cyrille.bruneau@etu.emse.fr, Mercier, Clément1 (AUTHOR), Leclerc, Lara1 (AUTHOR), Pourchez, Jérémie1 (AUTHOR) pourchez@emse.fr
Publikováno v:
Pharmaceutics. Nov2024, Vol. 16 Issue 11, p1396. 13p.
Autor:
Zhao, Heng1 (AUTHOR), Meng, Wanting1 (AUTHOR), Lv, Xing1 (AUTHOR), Li, Jing1 (AUTHOR), Cai, Zhigui1 (AUTHOR), Guo, Xingxing1 (AUTHOR), Wang, Zifeng2 (AUTHOR), Guo, Li2 (AUTHOR), Rong, Mingzhe2 (AUTHOR), Shen, Cong3 (AUTHOR), Liu, Dingxin2 (AUTHOR) liudingxin@mail.xjtu.edu.cn, Song, Liqiang1 (AUTHOR) songlq@fmmu.edu.cn
Publikováno v:
BMC Infectious Diseases. 9/12/2024, Vol. 24 Issue 1, p1-12. 12p.
Autor:
Song Li1, Xi-Cai Sun2, Zhong-Fei Wu1, Li Hu2, Jing-Jing Wang2, Min Yin1,3, Lei Cheng1,3 chenglei@jsph.org.cn, De-Hui Wang2 wangdehuient@sina.com
Publikováno v:
Journal of Infection in Developing Countries. 2024 Supplement, Vol. 18, pS81-S91. 11p.
Publikováno v:
Journal of Harran University Medical Faculty / Harran Üniversitesi Tıp Fakültesi Dergisi. 2024, Vol. 21 Issue 3, p476-482. 7p.
Autor:
Dai, Xuyao1 (AUTHOR) daixuyao000@163.com, Xu, Ruodan1 (AUTHOR) xurd@ibtcm.ac.cn, Li, Ning1 (AUTHOR) xurd@ibtcm.ac.cn
Publikováno v:
Cells (2073-4409). Aug2024, Vol. 13 Issue 16, p1353. 24p.
Autor:
Grandinetti, Roberto1 (AUTHOR) robertograndinetti93@gmail.com, Mussi, Nicole1 (AUTHOR), Rossi, Arianna1 (AUTHOR), Zambelli, Giulia1 (AUTHOR), Masetti, Marco1 (AUTHOR), Giudice, Antonella1 (AUTHOR), Pilloni, Simone1 (AUTHOR), Deolmi, Michela1 (AUTHOR), Caffarelli, Carlo1 (AUTHOR), Esposito, Susanna1 (AUTHOR), Fainardi, Valentina1 (AUTHOR) valentina.fainardi@unipr.it
Publikováno v:
Journal of Clinical Medicine. Aug2024, Vol. 13 Issue 15, p4558. 26p.
Autor:
Dwyer TJ; Discipline of Physiotherapy, Faculty of Health Sciences, University of Sydney, Sydney, Australia tiffany.dwyer@sydney.edu.au.; Dept of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, Australia., Daviskas E; Dept of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, Australia., Zainuldin R; Discipline of Physiotherapy, Faculty of Health Sciences, University of Sydney, Sydney, Australia.; Rehabilitation Dept, Ng Teng Fong General Hospital, Jurong Campus, NUHS Group, Singapore.; Physiotherapy, Health and Social Sciences Cluster, Singapore Institute of Technology, Singapore., Verschuer J; Dept of PET and Nuclear Medicine, Royal Prince Alfred Hospital, Sydney, Australia., Eberl S; Dept of PET and Nuclear Medicine, Royal Prince Alfred Hospital, Sydney, Australia., Bye PTP; Dept of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, Australia.; Central Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia., Alison JA; Discipline of Physiotherapy, Faculty of Health Sciences, University of Sydney, Sydney, Australia.; Sydney Local Health District, Sydney, Australia.
Publikováno v:
The European respiratory journal [Eur Respir J] 2019 Apr 18; Vol. 53 (4). Date of Electronic Publication: 2019 Apr 18 (Print Publication: 2019).